Dr. Maiti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2014 - 2017
NRS Medical College CalcuttaClass of 2011
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2022 - 2026
TX State Medical License 2020 - 2026
AZ State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
TN State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsLong-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
Cancer. 2025-01-01 - 2 citationsRAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.Junya Sango, Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour
Nature. 2024-12-01 - Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia...Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia
Leukemia. 2024-12-01
Journal Articles
- Secondary SyphilisPriyanka Bhugra, Abhishek Maiti, The New England Journal of Medicine
Lectures
- Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML).2019 ASCO Annual Meeting - 6/1/2019
- Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia m...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024- MD Anderson Research Highlights: EHA 2024 Special EditionJune 13th, 2024
- Acute Myeloid Leukemia Survivor Shows No Signs of Cancer After Clinical TrialMarch 1st, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
